These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Edwards CK Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I73-81. PubMed ID: 10577978 [TBL] [Abstract][Full Text] [Related]
3. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. McComb J; Gould T; Chlipala E; Sennelo G; Frazier J; Kieft G; Seely J; Edwards CK; Bendele A J Rheumatol; 1999 Jun; 26(6):1347-51. PubMed ID: 10381054 [TBL] [Abstract][Full Text] [Related]
4. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Bendele AM; McComb J; Gould T; Frazier J; Chlipala E; Seely J; Kieft G; Edwards CK Clin Exp Rheumatol; 1999; 17(5):553-60. PubMed ID: 10544838 [TBL] [Abstract][Full Text] [Related]
5. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Edwards CK; Martin SW; Seely J; Kinstler O; Buckel S; Bendele AM; Ellen Cosenza M; Feige U; Kohno T Adv Drug Deliv Rev; 2003 Sep; 55(10):1315-36. PubMed ID: 14499710 [TBL] [Abstract][Full Text] [Related]
6. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Bendele AM; McComb J; Gould T; Frazier J; Chlipala ES; Seely J; Kieft G; Wolf J; Edwards CK Inflamm Res; 1999 Aug; 48(8):453-60. PubMed ID: 10493163 [TBL] [Abstract][Full Text] [Related]
7. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Glossop JR; Dawes PT; Nixon NB; Mattey DL Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)]. Akiyama Y; Mimura T Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547 [TBL] [Abstract][Full Text] [Related]
9. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601 [TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Feige U; Hu YL; Gasser J; Campagnuolo G; Munyakazi L; Bolon B Cell Mol Life Sci; 2000 Sep; 57(10):1457-70. PubMed ID: 11078023 [TBL] [Abstract][Full Text] [Related]
12. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Mathsson L; Lampa J; Mullazehi M; Rönnelid J Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. Kubota A; Hasegawa K; Suguro T; Koshihara Y J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384 [TBL] [Abstract][Full Text] [Related]
14. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Kerwin BA; Chang BS; Gegg CV; Gonnelli M; Li T; Strambini GB Protein Sci; 2002 Jul; 11(7):1825-33. PubMed ID: 12070334 [TBL] [Abstract][Full Text] [Related]
15. Treatment of rheumatoid arthritis with etanercept. Genovese MC; Kremer JM Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043 [TBL] [Abstract][Full Text] [Related]